Online Test Measures Women’s Risk of Cancer Recurrence or Spread After Hormone Therapy

Online Test Measures Women’s Risk of Cancer Recurrence or Spread After Hormone Therapy
A newly developed online prognostic tool can determine whether a woman is at high risk of cancer recurrence or spread after receiving the standard five years of hormone therapy, and whether she could benefit from extended treatment, a study shows. The tool, called CTS5, is made for women with estrogen receptor-positive breast cancer and was developed by researchers at The Royal Marsden NHS Foundation Trust and Queen Mary University of London. "What we have developed could improve clinical practice, benefiting breast cancer patients by avoiding potentially unnecessary extended treatment,” Mitch Dowsett, head of The Royal Marsden Ralph Lauren Centre for Breast Cancer Research, professor at The Institute of Cancer Research, London, and study first author, said in a press release. “Clinicians require expertise and the best tools to help them make crucial decisions on treatment for patients, decisions that can make a difference to patients' quality of life," he added. The study, “Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5,” was published in the Journal of Clinical Oncology. Estrogen receptor (ER)-positive breast cancer accounts for about 85 percent of all breast cancer cases in the Western world. Patients are usually treated with surgery, chemotherapy and/or radiation, followed by hormone therapy for five years to lower their risk of cancer recurrence and spread. In more than half of the cases, however, cancer metastasis occurs after this five-year period. Extending hormone therapy reduces the rate of cancer recurrence, but the effects are modest and some patients may experience adverse side effects, includi
Subscribe or to access all post and page content.